Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Psychiatry
Volume 2014 (2014), Article ID 659715, 4 pages
http://dx.doi.org/10.1155/2014/659715
Case Report

Accelerated Hypertension after Venlafaxine Usage

1Department of Psychiatry, Kafkas University School of Medicine, 36000 Kars, Turkey
2Department of Cardiology, Kafkas University School of Medicine, Kars, Turkey
3Department of Emergency, Kafkas University School of Medicine, Kars, Turkey
4Department of Psychiatry, Kars State Hospital, Kars, Turkey

Received 17 February 2014; Revised 12 July 2014; Accepted 16 July 2014; Published 24 September 2014

Academic Editor: Ion George Anghelescu

Copyright © 2014 Yüksel Kıvrak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. C. Kessler, P. Berglund, O. Demler et al., “The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R),” Journal of the American Medical Association, vol. 289, no. 23, pp. 3095–3105, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Gutierrez, G. L. Stimmel, and J. Y. Aiso, “Venlafaxine: a 2003 update,” Clinical Therapeutics, vol. 25, no. 8, pp. 2138–2154, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Sadock and V. Sadock, Kaplan and Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry, Lippincott Williams and Wilkins, Philadelphia, Pa, USA, 9th edition, 2003.
  4. A. Çorapçıoğlu, Ö. Aydemir, M. Yıldız, and et al, DSM IV Eksen I bozuklukları (SCID-1) için yapılandırılmış klinik görüşme: Klinik versiyon, Hekimler Yayın Birligği, Ankara, Turkey, 1999.
  5. P. V. Tran, F. P. Bymaster, R. K. McNamara, and W. Z. Potter, “Dual monoamine modulation for improved treatment of major depressive disorder,” Journal of Clinical Psychopharmacology, vol. 23, no. 1, pp. 78–86, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. A. T. Harvey, R. L. Rudolph, and S. H. Preskorn, “Evidence of the dual mechanisms of action of venlafaxine,” Archives of General Psychiatry, vol. 57, no. 5, pp. 503–509, 2000. View at Publisher · View at Google Scholar · View at Scopus
  7. E. A. Muth, J. T. Haskins, J. A. Moyer, G. E. M. Husbands, S. T. Nielsen, and E. B. Sigg, “Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative,” Biochemical Pharmacology, vol. 35, no. 24, pp. 4493–4497, 1986. View at Publisher · View at Google Scholar · View at Scopus
  8. S. M. Stahl, “Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects,” Journal of Clinical Psychiatry, vol. 59, no. 18, pp. 23–29, 1998. View at Google Scholar · View at Scopus
  9. L. Ereshefsky and D. Dugan, “Review of the pharmacokinetics, pharmacogenetics, and drug interaction potential of antidepressants: focus on venlafaxine,” Depression and Anxiety, vol. 12, no. 1, pp. 30–44, 2000. View at Google Scholar · View at Scopus
  10. M. E. Thase, “Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients,” Journal of Clinical Psychiatry, vol. 59, no. 10, pp. 502–508, 1998. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Mbaya, F. Alam, S. Ashim, and D. Bennett, “Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder,” Human Psychopharmacology, vol. 22, no. 3, pp. 129–133, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. L. Rudolph, A. T. Derivan, and A. Khan, “The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database,” Journal of Clinical Psychopharmacology, vol. 16, supplement 2, no. 3, pp. 59S–61S, 1996. View at Google Scholar · View at Scopus
  13. D. E. McAlpine, J. M. Biernacka, D. A. Mrazek et al., “Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine,” Therapeutic Drug Monitoring, vol. 33, no. 1, pp. 14–20, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Preskorn, A. Patroneva, H. Silman et al., “Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers,” Journal of Clinical Psychopharmacology, vol. 29, no. 1, pp. 39–43, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Vinetti, V. Haufroid, A. Capron, J.-F. Classen, S. Marchandise, and P. Hantson, “Severe acute cardiomyopathy associated with venlafaxine overdose and possible role of CYP2D6 and CYP2C19 polymorphisms,” Clinical Toxicology, vol. 49, no. 9, pp. 865–869, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S.-F. Zhou, J.-P. Liu, and B. Chowbay, “Polymorphism of human cytochrome P450 enzymes and its clinical impact,” Drug Metabolism Reviews, vol. 41, no. 2, pp. 89–295, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Shinagawa, K. Otsuka, S. Murakami et al., “Seven-day (24-h) ambulatory blood pressure monitoring, self-reported depression and quality of life scores,” Blood Pressure Monitoring, vol. 7, no. 1, pp. 69–76, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. J. W. Hughes and C. M. Stoney, “Depressed mood is related to high-frequency heart rate variability during stressors,” Psychosomatic Medicine, vol. 62, no. 6, pp. 796–803, 2000. View at Publisher · View at Google Scholar · View at Scopus
  19. B. S. Jonas, P. Franks, and D. D. Ingram, “Are symptoms of anxiety and depression risk factors for hypertension? Longitudinal evidence from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study,” Archives of family medicine, vol. 6, no. 1, pp. 43–49, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. P. Danjou and D. Hackett, “Safety and tolerance profile of venlafaxine,” International Clinical Psychopharmacology, vol. 10, no. 2, pp. 15–20, 1995. View at Google Scholar · View at Scopus
  21. R. N. Khurana and T. E. Baudendistel, “Hypertensive crisis associated with venlafaxine,” The American Journal of Medicine, vol. 115, no. 8, pp. 676–677, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Pardal, T. John, and S. Rathee, “Venlafaxine induced hypertension:a case report,” Indian Journal of Psychiatry, vol. 43, no. 4, pp. 360–361, 2001. View at Google Scholar
  23. İ. Eren, İ. Ç. Inanli, and M. Şahin, “Venlafaksin kullanımının neden olduğu hipertansiyon: olgu sunumu,” Yeni Symposium, vol. 45, no. 2, pp. 51–53, 2007. View at Google Scholar